GI Cryo, Inc. is a start-up medtech company focused on the development of minimally-invasive cryoablation devices for the treatment of pancreatic cancer and other gastroenterological based diseased tissue. GI Cryo has licensed a novel ablation platform which includes the GastroCS cryoengine and FrostBite endoscopic ultrasound compatible cryoablation catheter (FrostBite platform). GI Cryo has assembled a strong team comprised of internationally recognized individuals who have a demonstrated track record in technology development, commercialization, and sales and marketing to spearhead the development and commercialization of the FrostBite platform. Collectively, this team has overseen the development and introduction of several medical devices and disposables in the cryosurgical arena. GI Cryo is now poised to complete engineering design and transition FrostBite into clinical trials, regulatory approval and manufacturing in support of commercial distribution once FDA cleared.